The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Randomised Double-blind Phase III Study to Compare the Efficacy and Safety of AZD2171 when added to 5-fluoracil Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) with the Efficacy and Safety of Placebo when added to FOLFOX or XELOX in Patients with Previously Untreated Metastatic Colorectal Cancer
- collapse An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate.
- collapse NSCLC PhaseII combo Car/Tax
- collapse A Phase II Randomised Double-blind Parallel Group Study to assess the efficacy andSafety of AZD2171 when added to chemotherapy (5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX)) to chemotherapy (FOLFOX) alone in patients with Previously Untreated Metastatic Colorectal Cancer
- collapse A Phase I Open Label Study of the Pharmacokinetics and Safety of cediranib (RECENTINTM AZD2171) following Single and Multiple Oral Doses in Patients with Advanced Solid Tumours with Various Degrees of Hepatic Dysfunction
- collapse A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy
- collapse A Phase I Open Label Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171 RECENTINTM) in Patients with Advanced Solid Tumours
- collapse A Phase I open-label dose escalation study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies
- collapse A Two-part Open-label Multi-centre Phase II Study in Patients with Advanced Solid Tumours consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmacokinetics of a Single Oral Dose of AZD2171 (Part A) Followed by a Randomised Parallel-group Protocol to Assess the Safety Tolerability and Efficacy of Multiple Doses of AZD2171 Administered as Either a Fixed Dose of 45 mg or an Individualised Dose Escalation Plan (Part B)
- collapse A Phase I Open Label Non-randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171 RECENTINTM) in Patients with Advanced Solid Tumours
